Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00311181 · ClinicalTrials.gov registry record · Phase 4
POWER (Pulse Width Optimized Waveform Evaluation Trial)
A Phase 4 study, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- Phase 4
- Development phase
- 217
- Enrollment target
NCT00311181: Completed Phase 4 study, sponsored by Abbott Medical Devices.
NCT00311181 is a Phase 4 study that has completed, run by Abbott Medical Devices. The registered enrollment target is 217 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00311181, a Phase 4 study, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 217 participants
- Enrollment target
Study Summary
The objective of this study is to compare the ULV (Upper Limit of Vulnerability)/DFT (Defibrillation Threshold) efficacy between the 2.5, 3.5 and 4.5 ms membrane time constant based biphasic defibrillation waveforms. This comparison will result in identifying the optimal membrane time constant when programming the "tuned" defibrillation waveform.
Interventions
- DEVICE Implantable Cardioverter Defibrillator (ICD), Cardiac Resynchronization Therapy (CRT-D)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2006-08 |
| Est. Completion | 2008-04 |
| Phase | Phase 4 |
What the finished NCT00311181 record still lists
NCT00311181 is an interventional study that assigns participants to a tested intervention. The registered 217 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 1 intervention - of which Implantable Cardioverter Defibrillator (ICD), Cardiac Resynchronization Therapy (CRT-D) is the first listed.
NCT00311181 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00311181 about?
NCT00311181 is a clinical study titled "POWER (Pulse Width Optimized Waveform Evaluation Trial)". The objective of this study is to compare the ULV (Upper Limit of Vulnerability)/DFT (Defibrillation Threshold) efficacy between the 2.5, 3.5 and 4.5 ms membrane time constant based biphasic defibrillation waveforms. This comparison will result in identifying the optimal membrane time constant when ...
What is the current status of trial NCT00311181?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 217 participants. The study started on 2006-08. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00311181?
The interventions under investigation include: Implantable Cardioverter Defibrillator (ICD), Cardiac Resynchronization Therapy (CRT-D) (DEVICE).
Who is sponsoring clinical trial NCT00311181?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00311181's enrollment target sits among peer trials
217 393rd of 2000 higher than 1,608 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05079282 · 217 participants · Phase 1
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
- NCT05470439 · 217 participants · NA
My Interprofessional Care Team for Adherence and Research Engagement Disparities
- NCT05981703 · 217 participants · Phase 1
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- NCT06342258 · 217 participants · Phase 1
COES: Curing Order Effects on Sealants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia